SkylineDx, a molecular diagnostics company, has published groundbreaking results from the PRospective Observational Multiple Myeloma Impact Study (PROMMIS), demonstrating the efficacy of the SKY92 gene expression profiling (GEP) classifier in improving risk stratification in multiple myeloma (MM) patients. This real-world study, published in the British Journal of Haematology, validates SKY92’s prognostic accuracy compared to conventional markers, highlighting its potential to guide personalized treatment decisions in MM care.
The PROMMIS study, conducted in collaboration with nine prominent U.S. hospitals and research centers, enrolled 251 newly diagnosed MM patients between 2018 and 2021. By integrating SKY92 into clinical practice, the study confirmed a significant enhancement in prognostic accuracy, leading to more personalized treatment planning for high-risk patients. Clinicians revised treatment plans in 50% of cases based on SKY92 results, showcasing the classifier’s ability to identify patients who may benefit from intensive therapies while sparing others unnecessary toxicities associated with aggressive treatments.
The study’s findings demonstrate that SKY92 improves risk stratification over traditional markers, with high-risk patients classified by SKY92 showing significantly shorter progression-free survival and overall survival. This molecular precision empowers clinicians to make more informed treatment decisions, increasing physician confidence in interpreting complex risk profiles and aligning therapies with patient prognosis. The integration of SKY92 into clinical decision-making represents a significant step towards personalized medicine in hematology.
Dr. Noa Biran, a study investigator, emphasized that SKY92 enables clinicians to better identify high-risk MM patients, facilitating the adoption of targeted therapeutic strategies. With SKY92 bringing molecular-level insights that surpass conventional risk assessment tools, it supports clinicians in delivering precise and effective care. This advancement underscores SkylineDx’s commitment to improving patient outcomes through innovative diagnostics and advancing precision medicine in hematology.
The SKY92 biomarker measures the activity of 92 genes in malignant myeloma plasma cells, providing crucial insights into the aggressiveness of the disease. It aids in determining the likelihood of treatment response, guiding clinicians in tailoring treatment approaches to individual patients. SKY92 is CE-IVD registered in Europe and available as a laboratory developed test from SkylineDx’s CAP/CLIA lab in San Diego, USA. SkylineDx’s focus on molecular diagnostics in oncology, inflammatory, and infectious diseases highlights its dedication to bridging the gap between academic research and clinically valuable diagnostic tools.
Takeaways:
– SKY92 gene expression profiling enhances risk stratification in multiple myeloma, enabling personalized treatment decisions.
– The PROMMIS study validates SKY92’s prognostic accuracy in real-world data, leading to improved patient outcomes.
– Integration of SKY92 into clinical practice increases physician confidence and supports targeted therapeutic strategies.
– SkylineDx’s commitment to innovation in molecular diagnostics underscores its role in advancing precision medicine.
Read more on finanznachrichten.de